601 related articles for article (PubMed ID: 17047044)
41. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells.
Safina A; Vandette E; Bakin AV
Oncogene; 2007 Apr; 26(17):2407-22. PubMed ID: 17072348
[TBL] [Abstract][Full Text] [Related]
42. Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations.
Grady WM; Willis JE; Trobridge P; Romero-Gallo J; Munoz N; Olechnowicz J; Ferguson K; Gautam S; Markowitz SD
Int J Cancer; 2006 Feb; 118(3):600-8. PubMed ID: 16108056
[TBL] [Abstract][Full Text] [Related]
43. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
44. Drosophila split ends homologue SHARP functions as a positive regulator of Wnt/beta-catenin/T-cell factor signaling in neoplastic transformation.
Feng Y; Bommer GT; Zhai Y; Akyol A; Hinoi T; Winer I; Lin HV; Cadigan KM; Cho KR; Fearon ER
Cancer Res; 2007 Jan; 67(2):482-91. PubMed ID: 17234755
[TBL] [Abstract][Full Text] [Related]
45. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells.
Uttamsingh S; Bao X; Nguyen KT; Bhanot M; Gong J; Chan JL; Liu F; Chu TT; Wang LH
Oncogene; 2008 Apr; 27(18):2626-34. PubMed ID: 17982486
[TBL] [Abstract][Full Text] [Related]
46. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
47. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis.
Oshima M; Oshima H; Taketo MM
Dev Biol; 1996 Oct; 179(1):297-302. PubMed ID: 8873772
[TBL] [Abstract][Full Text] [Related]
48. Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Song K; Cornelius SC; Danielpour D
Cancer Res; 2003 Aug; 63(15):4358-67. PubMed ID: 12907605
[TBL] [Abstract][Full Text] [Related]
49. Tumor progression in Apc(1638N) mice with Exo1 and Fen1 deficiencies.
Kucherlapati M; Nguyen A; Kuraguchi M; Yang K; Fan K; Bronson R; Wei K; Lipkin M; Edelmann W; Kucherlapati R
Oncogene; 2007 Sep; 26(43):6297-306. PubMed ID: 17452984
[TBL] [Abstract][Full Text] [Related]
50. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
Amendt C; Schirmacher P; Weber H; Blessing M
Oncogene; 1998 Jul; 17(1):25-34. PubMed ID: 9671311
[TBL] [Abstract][Full Text] [Related]
51. Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway.
Tomita H; Yamada Y; Oyama T; Hata K; Hirose Y; Hara A; Kunisada T; Sugiyama Y; Adachi Y; Linhart H; Mori H
Cancer Res; 2007 May; 67(9):4079-87. PubMed ID: 17483318
[TBL] [Abstract][Full Text] [Related]
52. Ephrin-A1 promotes the malignant progression of intestinal tumors in Apc(min/+) mice.
Shi L; Itoh F; Itoh S; Takahashi S; Yamamoto M; Kato M
Oncogene; 2008 May; 27(23):3265-73. PubMed ID: 18246128
[TBL] [Abstract][Full Text] [Related]
53. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene.
Böttinger EP; Jakubczak JL; Haines DC; Bagnall K; Wakefield LM
Cancer Res; 1997 Dec; 57(24):5564-70. PubMed ID: 9407968
[TBL] [Abstract][Full Text] [Related]
54. [Mechanism of resistance to growth inhibition by transforming growth factor-beta 1 (TGF-beta 1) in primary lung cancer and new molecular targets in therapy].
Gemma A; Uematsu K; Hagiwara K; Takenoshita S; Kudoh S
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1253-9. PubMed ID: 10945024
[TBL] [Abstract][Full Text] [Related]
55. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.
Zeilstra J; Joosten SP; Dokter M; Verwiel E; Spaargaren M; Pals ST
Cancer Res; 2008 May; 68(10):3655-61. PubMed ID: 18483247
[TBL] [Abstract][Full Text] [Related]
56. Hepatocyte growth factor activator inhibitor type 1 is a suppressor of intestinal tumorigenesis.
Hoshiko S; Kawaguchi M; Fukushima T; Haruyama Y; Yorita K; Tanaka H; Seiki M; Inatsu H; Kitamura K; Kataoka H
Cancer Res; 2013 Apr; 73(8):2659-70. PubMed ID: 23447577
[TBL] [Abstract][Full Text] [Related]
57. Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam1-/- mice.
Leung N; Turbide C; Balachandra B; Marcus V; Beauchemin N
Oncogene; 2008 Aug; 27(36):4943-53. PubMed ID: 18454175
[TBL] [Abstract][Full Text] [Related]
58. Altered expression of the receptor and ligand in the TGF beta signaling pathway in diffusely infiltrating colon carcinoma.
Nagayama S; Onodera H; Toguchida J; Imamura M
Anticancer Res; 2002; 22(6B):3545-54. PubMed ID: 12552954
[TBL] [Abstract][Full Text] [Related]
59. Transfection and expression of mutant p53 protein does not alter the in vivo or in vitro growth characteristics of the AA/C1 human adenoma derived cell line, including sensitivity to transforming growth factor-beta 1.
Williams AC; Browne SJ; Manning AM; Daffada P; Collard TJ; Paraskeva C
Oncogene; 1994 May; 9(5):1479-85. PubMed ID: 8152811
[TBL] [Abstract][Full Text] [Related]
60. The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
Dopeso H; Mateo-Lozano S; Mazzolini R; Rodrigues P; Lagares-Tena L; Ceron J; Romero J; Esteves M; Landolfi S; Hernández-Losa J; Castaño J; Wilson AJ; Ramon y Cajal S; Mariadason JM; Schwartz S; Arango D
Cancer Res; 2009 Sep; 69(18):7430-8. PubMed ID: 19738063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
